Neumora Therapeutics, Inc. Common Stock

NasdaqGS NMRA

Neumora Therapeutics, Inc. Common Stock Price to Earnings Ratio (P/E) on February 05, 2025: -1.07

Neumora Therapeutics, Inc. Common Stock Price to Earnings Ratio (P/E) is -1.07 on February 05, 2025, a 89.63% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • Neumora Therapeutics, Inc. Common Stock 52-week high Price to Earnings Ratio (P/E) is -1.02 on February 03, 2025, which is 4.12% above the current Price to Earnings Ratio (P/E).
  • Neumora Therapeutics, Inc. Common Stock 52-week low Price to Earnings Ratio (P/E) is -13.39 on February 16, 2024, which is -1,155.00% below the current Price to Earnings Ratio (P/E).
  • Neumora Therapeutics, Inc. Common Stock average Price to Earnings Ratio (P/E) for the last 52 weeks is -6.83.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
SV Wall Street
NasdaqGS: NMRA

Neumora Therapeutics, Inc. Common Stock

CEO Mr. Henry O. Gosebruch
IPO Date Sept. 15, 2023
Location United States
Headquarters 490 Arsenal Way
Employees 124
Sector Healthcare
Industries
Biotechnology Clinical Trials Mental Health Pharmaceuticals Vaccines
Description

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

StockViz Staff

February 7, 2025

Any question? Send us an email